2020
DOI: 10.1111/ced.14400
|View full text |Cite
|
Sign up to set email alerts
|

Fixed drug eruption secondary to adalimumab

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
3
0
1

Year Published

2022
2022
2024
2024

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(4 citation statements)
references
References 4 publications
0
3
0
1
Order By: Relevance
“…They are of particular interest given they are commonly used in the treatment of inflammatory diseases, such as psoriasis in dermatology. There are two reports of FDE with Adalimumab, one in a patient being treated for chronic plaque psoriasis (who subsequently tolerated golimumab) [46] and the other in a patient receiving treatment for ankylosing spondylitis [47]. Another patient with chronic plaque psoriasis developed a FDE secondary to ustekinumab [48].…”
Section: Drugs Causing Fdementioning
confidence: 99%
“…They are of particular interest given they are commonly used in the treatment of inflammatory diseases, such as psoriasis in dermatology. There are two reports of FDE with Adalimumab, one in a patient being treated for chronic plaque psoriasis (who subsequently tolerated golimumab) [46] and the other in a patient receiving treatment for ankylosing spondylitis [47]. Another patient with chronic plaque psoriasis developed a FDE secondary to ustekinumab [48].…”
Section: Drugs Causing Fdementioning
confidence: 99%
“…Sie sind von besonderem Interesse, da sie häufig für die Behandlung entzündlicher Erkrankungen ein gesetzt werden, wie Psoriasis in der Dermatologie. Es gibt zwei Berichte über FAE mit Adalimumab, einen bei einem Patienten, der wegen chronischer PlaquePsoriasis behan delt wurde (und anschließend Golimumab gut vertrug) [46], und einen bei einem Patienten, der wegen Spondylitis anky losans behandelt wurde [47]. Bei einem anderen Patienten mit chronischer PlaquePsoriasis entwickelte sich ein FAE als Folge einer Behandlung mit Ustekinumab [48].…”
Section: Gastrointestinales Systemunclassified
“…For example, adalimumab, a humanized monoclonal antibody that blocks tumour necrosis factor (TNF)-α activity, is licensed for the treatment of psoriasis and other inflammatory diseases. However, several cases of paradoxical psoriasis and erythema-like eruption have been reported following treatment with adalimumab (8,9). Secukinumab, an anti-interleukin (IL)-17A IgG1-κ monoclonal antibody, is approved for use in psoriasis, psoriatic arthritis, and ankylosing spondylitis.…”
Section: Letters To Editor Rheumatologymentioning
confidence: 99%